Rather than utilizing passive transport via the EPR effect for drug delivery to tumor, nab-paclitaxel relies on active albumin transport pathways including the gp60/caveolae-mediated albumin transcytosis across tumor blood vessel endothelium and potential association with tumoral SPARC to achieve enhanced drug accumulation in tumors (10). This evidence concerns the gene SPARC and neoplasm.